Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds.
Søren Møller obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren Møller has academic training as postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Novo Seeds, Søren Møller served as global manager of Genomics at Novozymes. Before Novozymes, Søren Møller was CSO and Vice President of R&D at Exiqon A/S. During Søren Møller’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren Møller worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Søren Møller serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren Møller has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).